Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 50, Issue 1, 2017, Pages 93-99

  Akhter, T ^a   Wikstrom A K ^a   Larsson, M ^a   Larsson, A ^a   Wikstrom G ^a   Naessen, T ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

cardiovascular disease; common carotid artery; fms like tyrosine kinase 1; fms like tyrosine kinase 1:placental growth factor ratio; high frequency ultrasonography; intima:media ratio; placental growth factor; pre eclampsia

Indexed keywords

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; AGING; BLOOD; CASE CONTROL STUDY; COMMON CAROTID ARTERY; DIAGNOSTIC IMAGING; FEMALE; FETUS ECHOGRAPHY; HUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY;

ADULT; AGING; BIOMARKERS; CAROTID ARTERY, COMMON; CASE-CONTROL STUDIES; FEMALE; HUMANS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; ULTRASONOGRAPHY, PRENATAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 85016391387     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.15981     Document Type: Article

References (43)

1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53–56.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130–137.
3. Bernardi F, Guolo F, Bortolin T, Petronilho F, Dal-Pizzol F. Oxidative stress and inflammatory markers in normal pregnancy and preeclampsia. J Obstet Gynaecol Res 2008; 34: 948–951.
4. Sargent IL, Borzychowski AM, Redman CW. Nk cells and human pregnancy - an inflammatory view. Trends Immunol 2006; 27: 399–404.
5. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11: 309–316.
6. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23: 359–372.
7. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR, Espinoza J, Goncalves LF, Edwin S, Mazor M. Evidence supporting that the excess of the svegfr-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 2005; 18: 9–16.
8. World Health Federation. http://www.world-heart-federation.org/press/fact-sheets/cardiovascular-disease-risk-factors [Accessed 2 November 2016].
9. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005; 48: 372–386.
10. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179: 1539–1544.
11. Leanos-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leanos R, Romero-Arauz JF, Ayala-Mendez JA, Ulloa-Aguirre A. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. J Hypertens 2012; 30: 2173–2181.
12. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, plgf and sflt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837–842.
13. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683.
14. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y. Usefulness of soluble fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 2009; 104: 1478–1483.
15. Kameda R, Yamaoka-Tojo M, Makino A, Wakaume K, Nemoto S, Kitasato L, Shimohama T, Tojo T, Machida Y, Izumi T. Soluble fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation. Int Heart J 2013; 54: 133–139.
16. Chung NA, Makin AJ, Lip GY. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: Development and application of an immunoassay. Eur J Clin Invest 2003; 33: 529–535.
17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.
18. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses. Am Heart J 2008; 156: 918–930.
19. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. BMJ 2007; 335: 974.
20. Kádár A, Mózes G, Illyés G, Schönfeld T, Kulka J, Sipos B, Glasz T, Tőkés AM, Szik A. World Health Organization (WHO) and the World Heart Federation (WHF) pathobiological determinants of atherosclerosis in youth study (WHO/WHF PBDAY Study) 1986–1996. Histomorphometry and histochemistry of atherosclerotic lesions in coronary arteries and the aorta in a young population. Nutr Metab Cardiovasc Dis 1999; 9: 220–227.
21. Gussenhoven EJ, Essed CE, Lancée CT, Mastik F, Frietman P, van Egmond FC, Reiber J, Bosch H, van Urk H, Roelandt J, et al. Arterial wall characteristics determined by intravascular ultrasound imaging: an in vitro study. J Am Coll Cardiol 1989; 14: 947–952.
22. Akhter T, Wikstrom AK, Larsson M, Naessen T. Individual common carotid artery wall layer dimensions, but not carotid intima-media thickness, indicate increased cardiovascular risk in women with preeclampsia: An investigation using noninvasive high-frequency ultrasound. Circ Cardiovasc Imaging 2013; 6: 762–768.
23. Akhter T, Larsson M, Wikstrom AK, Naessen T. Thicknesses of individual layers of artery wall indicate increased cardiovascular risk in severe pre-eclampsia. Ultrasound Obstet Gynecol 2014; 43: 675–680.
24. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996; 85: 843–848.
25. Cnossen JS, Vollebregt KC, de Vrieze N, ter Riet G, Mol BW, Franx A, Khan KS, van der Post JA. Accuracy of terial pressure and blood pressure measurements in predicting pre-eclampsia: Systematic review and meta-analysis. BMJ 2008; 336: 1117–1120.
26. Naessen T, Rodriguez-Macias K. Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries. An investigation using noninvasive high-frequency ultrasound. Atherosclerosis 2006; 189: 387–392.
27. Rodriguez-Macias KA, Lind L, Naessen T. Thicker carotid intima layer and thinner media layer in subjects with cardiovascular diseases. An investigation using noninvasive high-frequency ultrasound. Atherosclerosis 2006; 189: 393–400.
28. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26: 563–573.
29. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble vegfr-1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443–454.
30. Shibuya M. Structure and function of vegf/vegf-receptor system involved in angiogenesis. Cell Struct Funct 2001; 26: 25–35.
31. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109: 1368–1374.
32. Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander JM. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. Am J Obstet Gynecol 2012; 207: 140.e20–26.
33. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Olovsson M. Early postpartum changes in circulating pro- and anti-angiogenic factors in early-onset and late-onset pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 146–153.
34. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285: 1607–1612.
35. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: An indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004; 286: H1389–1393.
36. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 5–15.
37. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007; 109: 1368–1374.
38. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006; 195: 255–259.
39. Straughen JK, Kumar P, Misra VK. The effect of maternal soluble fms-like tyrosine kinase 1 during pregnancy on risk of preterm delivery. J Matern Fetal Neonatal Med 2012; 25: 1879–1883.
40. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9–23.
41. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: Opportunities for intervention and screening? BMJ 2002; 325: 157–160.
42. Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 2014; 161: 249–260.
43. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: The osteoporosis prevention and arterial effects of tibolone (opal) study. Eur Heart J 2006; 27: 746–755.